← GIP/GLP-1 & amylin agonists × body weight & compositionTrialJournal of the American College of Cardiology2025
Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy.
Christopher M Kramer et al.PubMed ↗Publisher ↗
A secondary analysis of NCT04847557. The trial’s primary report, PMID 39555826, speaks for it on the map; the numbers here are shown and do not vote.
What the trial testedrandomised · 175 people · 2025
Randomised comparisonProbably lowered body weight & composition
Doesn’t vote: a later paper about the trial
−45.0mL−69.0 to −22.0
As reported
difference −45.0 mL, 95% CI −69.0 to −22.0
One number in the abstract
Where each one falls
Where it lands on the map
the abstract, start to end
… tissue decreased in the treated group by 45 mL (95% CI: -69 to -22 mL) when …
← favours treatmentfavours comparator →
could be chanceBody weight & composition
−45.0−69.0 to −22.0
GIP/GLP-1 & amylin agonistsBody weight & composition
99 papers cite itlatest 60 shown
this paperpooled ittrialcites it